Switch theme
Sign up to access all valuation multiples
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune systems.
2014
12
LTM Revenue n/a
LTM EBITDA n/a
$417M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Regencell Bioscience has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Regencell Bioscience achieved revenue of n/a and an EBITDA of -$4.0M.
Regencell Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Regencell Bioscience valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$5.5M | -$4.0M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$7.4M | -$5.9M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Regencell Bioscience's stock price is $33.
Regencell Bioscience has current market cap of $425M, and EV of $417M.
See Regencell Bioscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $417M | $425M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Regencell Bioscience has market cap of $425M and EV of $417M.
Regencell Bioscience's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Regencell Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Regencell Bioscience and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $417M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -104.4x | XXX | XXX | XXX |
| P/E | -98.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -104.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpRegencell Bioscience's NTM/LTM revenue growth is n/a
Regencell Bioscience's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Regencell Bioscience's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Regencell Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Regencell Bioscience and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -27% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Regencell Bioscience acquired XXX companies to date.
Last acquisition by Regencell Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Regencell Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Regencell Bioscience founded? | Regencell Bioscience was founded in 2014. |
| Where is Regencell Bioscience headquartered? | Regencell Bioscience is headquartered in United States of America. |
| How many employees does Regencell Bioscience have? | As of today, Regencell Bioscience has 12 employees. |
| Who is the CEO of Regencell Bioscience? | Regencell Bioscience's CEO is Mr. Yat-Gai Au. |
| Is Regencell Bioscience publicy listed? | Yes, Regencell Bioscience is a public company listed on NAS. |
| What is the stock symbol of Regencell Bioscience? | Regencell Bioscience trades under RGC ticker. |
| When did Regencell Bioscience go public? | Regencell Bioscience went public in 2021. |
| Who are competitors of Regencell Bioscience? | Similar companies to Regencell Bioscience include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Regencell Bioscience? | Regencell Bioscience's current market cap is $425M |
| Is Regencell Bioscience profitable? | Yes, Regencell Bioscience is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
